Initial Antibiotic Treatment for Pancreatic Abscess

Antibiotic Selection

The World Journal of Emergency Surgery recommends broad-spectrum intravenous antibiotics with carbapenems (meropenem 1g IV q6h or imipenem 500mg IV q6h by extended infusion) as first-line therapy for pancreatic abscess, covering aerobic and anaerobic gram-negative and gram-positive organisms 1, 2
Carbapenems (imipenem, meropenem, doripenem) achieve the highest pancreatic tissue concentrations and provide comprehensive coverage against the polymicrobial flora typical of pancreatic infections 1, 3, 2
Meropenem 1g IV q6h by extended infusion or continuous infusion is recommended for immunocompetent patients 1

Metronidazole plus levofloxacin can be used as an alternative regimen, particularly in scenarios with beta-lactam allergy, with levofloxacin 500mg IV once daily and metronidazole 500mg IV q8h providing adequate coverage when carbapenems cannot be used 1, 4, 3
The combination of metronidazole and levofloxacin may be used as step-down therapy after initial carbapenem therapy and clinical improvement 4, 3

The empiric regimen must cover aerobic gram-negative organisms (E. coli, Klebsiella, Enterobacter), anaerobic organisms (Bacteroides species), and gram-positive organisms (Enterococcus, Staphylococcus) 1, 3

For patients with risk factors for MDR organisms, imipenem/cilastatin-relebactam 1.25g IV q6h by extended infusion, meropenem/vaborbactam 2g/2g IV q8h by extended infusion, or ceftazidime/avibactam 2.5g IV q8h by extended infusion plus metronidazole 500mg IV q8h are recommended 1
Gram-positive coverage with linezolid 600mg IV q12h or teicoplanin should be added to the regimen 1

The American College of Physicians and other guideline societies recommend a duration of therapy of 7 days if adequate source control is achieved and clinical improvement occurs, with a maximum duration of 14 days without documented persistent infection on culture 2, 5

Aminoglycosides (gentamicin, tobramycin) should be avoided due to inadequate pancreatic tissue concentrations 3
Antifungal coverage is not routinely recommended but should be considered if multiple risk factors for invasive candidiasis exist 1, 3, 2
Source control is mandatory, with antibiotics combined with drainage procedures (CT-guided percutaneous drainage or surgical intervention) for treatment success 1, 3, 2